Replimune Group (Nasdaq:REPL) - Hisse Senedi Fiyatı, Haberler ve Analizler

REPL Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Replimune Group, Inc. kanseri tedavi etmek için onkolitik immünoterapilerin geliştirilmesine odaklanmaktadır.

Şirket hakkında

REPL temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Trading at 54.4% below our estimate of its fair value

Revenue is forecast to grow 58.67% per year

Analysts in good agreement that stock price will rise by 30.3%

Risk Analizi

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Replimune Group, Inc. Rakipler

Intercept Pharmaceuticals

NasdaqGS:ICPT

US$794.7m

Perspective Therapeutics

NYSEAM:CATX

US$815.2m

Dianthus Therapeutics

NasdaqCM:DNTH

US$822.6m

89bio

NasdaqGM:ETNB

US$968.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Replimune Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$11.90
52 Haftanın En Yüksek Seviyesi	US$14.72
52 Haftanın En Düşük Seviyesi	US$4.92
Beta	1.21
11 Aylık Değişim	2.94%
3 Aylık Değişim	21.68%
1 Yıllık Değişim	-7.54%
33 Yıllık Değişim	-64.30%
5 Yıllık Değişim	-30.85%
Halka arzdan bu yana değişim	-21.50%

Son Haberler & Güncellemeler

Replimune: Strong Data In A Highly Differentiated Space

Sep 03

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Aug 16

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Hissedar Getirileri

	REPL	US Biotechs	US Pazar
7D	-1.2%	-0.7%	-1.6%
1Y	-7.5%	19.8%	30.8%

Getiri vs. Endüstri: REPL underperformed the US Biotechs industry which returned 19.8% over the past year.

Getiri vs Piyasa: REPL underperformed the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement	7.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: REPL has not had significant price volatility in the past 3 months compared to the US market.

Zaman İçindeki Volatilite: REPL's weekly volatility (8%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	331	Sush Patel	www.replimune.com

Klinik aşamada bir biyoteknoloji şirketi olan Replimune Group, Inc. kanseri tedavi etmek için onkolitik immünoterapilerin geliştirilmesine odaklanmaktadır. Şirketin tescilli tümöre yönelik onkolitik immünoterapi ürün adayları, kansere karşı bağışıklık sistemini aktive etmek üzere tasarlanmış ve amaçlanmıştır. Şirketin öncü ürün adayı, GALV-GP R(-) ve insan GM-CSF'sini ifade eden HSV-1'in seçici olarak çoğalan bir versiyonu olan ve çeşitli solid tümörler için Faz I/II klinik çalışmalarında bulunan RP1'dir.

Replimune Group, Inc. Temel Bilgiler Özeti

Replimune Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REPL temel i̇stati̇sti̇kler
Piyasa değeri	US$813.02m
Kazançlar(TTM)	-US$220.01m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.7x

F/K Oranı

REPL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REPL gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$220.01m
Kazançlar	-US$220.01m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.22
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	10.6%

REPL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

REPL Stoklara Genel Bakış

Ödüller

Risk Analizi

Replimune Group, Inc. Rakipler

NasdaqGS:ICPT

US$794.7m

NYSEAM:CATX

US$815.2m

NasdaqCM:DNTH

US$822.6m

NasdaqGM:ETNB

US$968.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Recent updates

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock